The new solution bundle is intended to tackle challenges and evolving requirements in oncology clinical research.
Using the experience of the company in approximately 1,000 cancer trials, Oncology Complete merges established trial optimisation technologies with in-house clinical capabilities to meet the complete needs of oncology studies while streamlining trial management.
The company’s SmartSignals eCOA, eConsent, and RTSM software solutions are included in the combined package to offer a more predictable trial experience for all stakeholders.
The core of the solution is an adaptable eCOA solution that meets the varying regulatory needs for patient-reported outcomes measurement in oncology trials.
This facilitates at-home or at-site evaluations while inbuilt patient engagement and video visit features promote a better patient experience.
Automated data record making and reconciliation features for investigative sites simplify workflows and boost adherence to protocol such as guaranteeing compliance with inclusion/exclusion standards.
Furthermore, the solution facilitates single-contract procurement and expedited trial launches to aid sponsors and clinical research organisations in meeting strategic operational goals.
The new offering can be applied to any cancer programme from early-phase, local trials to pivotal multinational studies.
Signant chief product officer Sanjiv Waghmare said: “Now with Oncology Complete, we’re offering a full-featured oncology evidence generation platform combined with Signant’s expert service and support, all under one contract.
“From patient-reported outcomes data capture to informed consent, patient engagement, video visits and medication management, our single-source approach enables sponsors to conduct simple and complex trials efficiently and cost-effectively.”